Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro potency assay designed to characterize the anti-fibrotic mechanism of action of the Capricor’s lead investigational product, Deramiocel, which is currently in late-stage development for the treatment of Duchenne muscular dystrophy, DMD. The publication, titled “A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel,” showed results that further elucidate the biological activity of cardiosphere-derived cells, the active component of Deramiocel. The study found that CDCs, through their secreted exosomes and soluble factors, suppressed collagen I and III gene expression in primary human fibroblasts in vitro, supporting their potential to modulate fibrotic processes associated with disease progression.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics management to meet with Piper Sandler
- Largest borrow rate increases among liquid names
- Capricor Therapeutics’ Deramiocel Progress and FDA Clarity Underpin Buy Rating
- Starbucks announces restructuring, CoreWeave expands OpenAI pact: Morning Buzz
- Optimistic Buy Rating for Capricor Therapeutics Driven by Regulatory Progress and Strategic Positioning